Biopharmx Corp’s (BPMX) “Buy” Rating Reiterated at Maxim Group
Maxim Group reissued their buy rating on shares of Biopharmx Corp (NASDAQ:BPMX) in a research note published on Wednesday, MarketBeat.com reports. Maxim Group currently has a $1.50 target price on the stock, down from their prior target price of $3.00.
A number of other brokerages also recently issued reports on BPMX. Roth Capital set a $3.00 price target on Biopharmx Corp and gave the company a buy rating in a report on Saturday, June 3rd. HC Wainwright set a $3.00 price target on Biopharmx Corp and gave the company a buy rating in a report on Thursday, June 15th.
Shares of Biopharmx Corp (NASDAQ:BPMX) traded up 6.087% during trading on Wednesday, hitting $0.305. 542,089 shares of the company traded hands. The stock’s market capitalization is $22.61 million. The company has a 50-day moving average of $0.31 and a 200-day moving average of $0.48. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $0.90.
Biopharmx Corp (NASDAQ:BPMX) last announced its quarterly earnings results on Wednesday, September 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. Equities analysts expect that Biopharmx Corp will post ($0.25) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/16/biopharmx-corps-bpmx-buy-rating-reiterated-at-maxim-group.html.
In other Biopharmx Corp news, major shareholder Franklin Resources Inc purchased 250,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was purchased at an average cost of $0.34 per share, with a total value of $85,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of hedge funds and other institutional investors have recently modified their holdings of BPMX. Vanguard Group Inc. lifted its stake in Biopharmx Corp by 324.6% in the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after buying an additional 1,478,338 shares during the last quarter. Vivo Capital LLC lifted its stake in Biopharmx Corp by 10.0% in the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after buying an additional 1,282,052 shares during the last quarter. Finally, Virtu KCG Holdings LLC lifted its stake in Biopharmx Corp by 366.2% in the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after buying an additional 395,424 shares during the last quarter.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.